Family Care Hospitals Ltd

As of 04-Nov, Family Care Hospitals Ltd's stock price is at 4.14, showing a slight increase but still trading below key moving averages. The stock has underperformed significantly over various periods, with a year-to-date decline of 37.84%, indicating ongoing challenges relative to the market.

As of October 29, 2025, Family Care is considered overvalued and risky due to severe profitability issues, reflected in a negative PE ratio of -3.62 and a year-to-date return of -35.44%, significantly underperforming compared to its peers like Max Healthcare and Apollo Hospitals.

Family Care's historical performance has been volatile, with net sales peaking at 47.30 Cr in March 2023 but plummeting to 7.90 Cr by March 2025, alongside significant declines in operating income and total assets. Despite a rise in operating profit due to negative expenditures, profit before tax fell sharply to -44.47 Cr in March 2025.

Family Care Hospitals' latest results are concerning, with a 98.20% revenue decline to ₹0.07 crores and a net loss of ₹4.61 crores, indicating severe operational distress and potential viability issues. The company's financial health has deteriorated significantly, with a 76.94% drop in shareholder funds and negative cash flow.

Family Care's historical performance has been volatile, with net sales peaking at 47.30 Cr in March 2023 but plummeting to 7.90 Cr by March 2025, alongside a significant decline in profitability and negative cash flow in the latest year. Total assets and liabilities also decreased during this period, reflecting overall financial instability.

As of October 27, 2025, Family Care is considered undervalued with a fair valuation grade, a PE ratio of 0.80, an EV to EBITDA of 0.97, and a high ROE of 219.63%, making it a compelling investment compared to peers like Max Healthcare and Apollo Hospitals, despite a year-to-date stock decline of 34.08%.

As of October 24, 2025, Family Care is considered overvalued with a valuation grade of expensive, indicated by a low PE ratio of 0.82 and poor performance compared to peers and the Sensex, showing a YTD return of -32.88%.

As of October 24, 2025, Family Care is considered overvalued with a valuation grade of expensive, despite strong operational metrics, as indicated by its PE ratio of 0.82 and a year-to-date return of -32.88%, significantly underperforming against the Sensex.

As of October 24, 2025, Family Care is considered overvalued with a valuation grade shift from fair to expensive, reflected by a low PE ratio of 0.82 and poor stock performance compared to industry peers and the Sensex.

The next results date for Family Care is 28 October 2025.

As of October 23, 2025, Family Care is fairly valued with a PE ratio of 0.80 and strong financial metrics, but has underperformed the Sensex with a year-to-date return of -34.23%, suggesting it may be a buying opportunity despite market concerns.

As of October 20, 2025, Family Care is considered overvalued with a PE Ratio of 0.81 and an EV to EBITDA of 0.97, significantly higher than peers like Apollo Hospitals and Max Healthcare, and has underperformed the Sensex with a year-to-date return of -33.48%.

As of October 17, 2025, Family Care is fairly valued with a PE ratio of 0.79 and an EV to EBITDA ratio of 0.95, indicating strong growth potential despite a year-to-date return of -35.14%, especially when compared to peers like Max Healthcare and Apollo Hospitals.

As of October 17, 2025, Family Care is fairly valued with a PE ratio of 0.79 and an EV to EBITDA of 0.95, indicating strong profitability compared to peers like Max Healthcare and Apollo Hospitals, despite a year-to-date stock decline of 35.14% against the Sensex's 7.44% gain, suggesting potential for recovery in the healthcare sector.

As of October 17, 2025, Family Care is fairly valued with a PE ratio of 0.79 and strong financial metrics, making it more attractive compared to peers like Max Healthcare and Apollo Hospitals, despite its recent stock performance lagging behind the Sensex.

As of 17-Oct, Family Care Hospitals Ltd's stock price is declining at 4.32, down 1.82%, and has underperformed significantly with a year-to-date drop of 35.14% compared to the Sensex's gain. Despite increased investor participation, the stock continues to trade below key moving averages, indicating a bearish trend.